Spectrum Pharmaceuticals Inc. said Thursday it has reached an agreement to sell its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.L.C. Spectrum said it will receive $160 million in an upfront cash payment and be entitled to up to $140 million milestone payments on reaching certain regulatory and sales goals. The company said its staff will be reduced by about 40% with most transitioning to Acrotech. The remaining staff will focus on the launch of it two late-stage pipeline treatments, ROLONTIS and poziotinib, which are cancer drugs. Shares were halted for the news, but have fallen 46.1% in the last 12 months, while the S&P 500 has fallen 6.7%.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Howard Schultz says he would improve Obamacare, force Big Pharma to negotiate on drug pricesThe former Starbucks CEO and independent presidential hopeful offered an early glimpse Wednesday of his healthcare platform. Similar in many ways to Obamacare, Schultz's proposals could also be vulnerable to the same stumbling blocks.
Read more »
Samsung Faces Resistance From Big Pharma in the U.S.Samsung’s foray into the U.S. biologic-drug market is proving tougher than expected, as the South Korean company faces strong resistance from established pharmaceutical companies while doctors and patients are reluctant to switch to biosimilars.
Read more »
Would Big Pharma Pay for the Wall?Ensuring the federal government reopens soon is very much in the pharmaceutical industry’s interest. Absent a deal, the FDA will run out of funds to process applications for new drugs.
Read more »
Trial begins for pharma exec accused of using 'bribes and fraud' to sell fentanylTrial begins for pharma exec accused of using 'bribes and fraud' to sell fentanyl.
Read more »
U.S. lawmaker launches investigation into pharma drug pricingA top U.S. lawmaker launched an investigation into pharmaceutical industry prici...
Read more »
Novartis CEO Who Wanted To Bring Tech Into Pharma Now Explains Why It's So HardWe need to bring our best technology – biological and digital – and our most creative people together to work on this monumental challenge. One clear take-away from the Narasimhan interview: pharma is at the very earliest stages of figuring out how to do this.
Read more »